Aclarion | MedPath

USC Spine Center Joins Pivotal CLARITY Trial to Evaluate Nociscan for Chronic Low Back Pain

4 days ago

• Keck Medical Center of USC has joined the CLARITY trial to evaluate Aclarion's Nociscan technology, which uses MR Spectroscopy and AI to identify sources of chronic low back pain. • The randomized, multi-center CLARITY trial will enroll 300 patients across prestigious institutions including Johns Hopkins Medicine, Northwestern Medicine, and Texas Back Institute. • Nociscan is the first evidence-supported platform to noninvasively distinguish between painful and nonpainful discs in the lumbar spine, potentially transforming diagnosis and treatment for 266 million people worldwide with degenerative spine disease.

Northwestern Medicine Selected as First Site for Pivotal CLARITY Trial Testing Nociscan's Low Back Pain Technology

4 months ago

• Northwestern Medicine, a leading clinical research institution that conducted over 6,900 studies in 2024, has been selected as the initial site for Aclarion's CLARITY trial investigating Nociscan technology. • The CLARITY trial, a fully-funded randomized study of 300 patients, aims to evaluate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain through MR Spectroscopy and AI technology. • Led by Dr. Nicholas Theodore of Johns Hopkins, the study will compare surgical outcomes between physicians with and without access to Nociscan's biomarker data for treating discogenic low back pain.

Aclarion Expands CLUE Trial for Nociscan in Chronic Low Back Pain Diagnosis

9 months ago

• Aclarion's CLUE trial, evaluating Nociscan's impact on chronic low back pain treatment, expands to New Jersey with Dr. Justin Kubeck joining the study. • The CLUE trial aims to gather real-world evidence on how Nociscan's AI-driven data influences treatment decisions for patients with chronic low back pain. • Nociscan is a SaaS platform that analyzes chemical biomarkers to distinguish between painful and nonpainful discs, aiding physicians in optimizing treatment strategies. • Aclarion seeks to demonstrate Nociscan's clinical utility to payers, potentially driving early coverage decisions for the diagnostic tool.